Summary Background The World Health Organization (WHO) released updated guidelines for the screening, care and treatment of patients with chronic hepatitis C virus (HCV) infection. Methods A previously described HCV disease burden model was used to develop a “WHO scenario” to achieve the WHO recommendations of a 90% reduction in incidence and 65% reduction in […]
Summary The hepatitis C virus (HCV) epidemic was forecasted through 2030 for 15 countries in Europe, the Middle East and Asia, and the relative impact of two scenarios was considered: [1] increased treatment efficacy while holding the annual number of treated patients constant and [2] increased treatment efficacy and an increased annual number of treated […]
Summary The total number, morbidity and mortality attributed to viraemic hepatitis C virus (HCV) infections change over time making it difficult to compare reported estimates from different years. Models were developed for 15 countries to quantify and characterize the viraemic population and forecast the changes in the infected population and the corresponding disease burden from […]
Summary Detailed, country-specific epidemiological data are needed to characterize the burden of chronic hepatitis C virus (HCV) infection around the world. With new treatment options available, policy makers and public health officials must reconsider national strategies for infection control. In this study of 15 countries, published and unpublished data on HCV prevalence, viraemia, genotype, age […]
Summary Objective In Switzerland, fewer than 40% of hepatitis C virus (HCV) infected individuals have been diagnosed. The aim of this project was to analyse the distribution of HCV cases in order to develop better detection strategies. Study Design Historical data on the HCV-infected population in Switzerland were obtained from published literature, unpublished data and […]
Summary On-therapy decline or normalization of liver enzyme levels is often observed following initiation of interferon-based hepatitis C virus (HCV) antiviral treatment and may reflect response to therapy and decreasing HCV RNA levels (1,2). On-treatment alanine aminotransferase (ALT) level elevation may be associated with persistent viremia (3–5). The value of enzymatic response in predicting sustained […]
Summary Background Chronic hepatitis C virus infection is a major cause of liver disease in Switzerland and carries a significant cost burden. Currently, only conservative strategies are in place to mitigate the burden of hepatitis C in Switzerland. This study expands on previously described modeling efforts to explore the impact of: no treatment, and treatment […]
Summary Background This manuscript serves as an update to position papers published in 2014 based on the available Belgian hepatitis C virus (HCV) epidemiological data. Methods Building on the current standard of care (2015: 900 = F3 patients treated with 70-85% SVR), four new scenarios were developed to achieve the goals of near viral elimination […]
Summary The hepatitis C virus (HCV) epidemic was forecasted through 2030 for 15 countries, and the relative impact of two scenarios was considered: (i) increased treatment efficacy while holding the treated population constant and (ii) increased treatment efficacy and increased annual treated population. Increasing levels of diagnosis and treatment, in combination with improved treatment efficacy, […]
Summary Morbidity and mortality attributable to chronic hepatitis C virus (HCV) infection are increasing in many countries as the infected population ages. Models were developed for 15 countries to quantify and characterize the viremic population, as well as estimate the number of new infections and HCV related deaths from 2013 to 2030. Expert consensus was […]
English 
Spanish 
French 
Chinese 
Russian 
Arabic